Clinical validation of PEA-driven Olink proteomic discovery: INPP1 and ARHGAP25 serum biomarkers improve early breast cancer diagnosis
Translational Oncology, 2026
Huang J., Gao L., Glazutdinova L., Ji X., Zhang J., Lu Y., Zhang S., Liu Y.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology | Patient Stratification | Serum |  Olink Explore 3072/384 |
Abstract
Background
Breast cancer is the most common malignant tumor in women all over the world, accounting for 15% of all female cancer-related mortality. Due to the limited sensitivity of current serum biomarkers (such as CA15–3, CEA) and the invasiveness of imaging/biopsy methods, early detection of breast cancer is still challenging. The purpose of this study is to use Olink proteomics to identify new diagnostic markers of breast cancer and integrate them into a multi-protein diagnostic model to improve the accuracy of early detection.
Methods
Serum proteomic profiling was performed via Olink’s proximity extension assay (PEA) in a discovery cohort (15 breast cancer patients vs. 16 healthy controls). Differentially expressed proteins were analyzed to construct a diagnostic model, which was validated in an independent cohort (111 breast cancer patients [56 early-stage, 55 late-stage] vs. 95 healthy controls).
Results
The combination of INPP1 (first reported as downregulated in breast cancer serum) and ARHGAP25 demonstrated high diagnostic accuracy, achieving AUCs of 0.8458 (discovery cohort) and 0.8506 (validation cohort). Notably, the model retained efficacy in early-stage detection (AUC = 0.7598).
Conclusion
This study identifies a novel serum protein panel (INPP1/ARHGAP25) as a minimally invasive tool for breast cancer diagnosis, particularly valuable for early-stage screening. The findings underscore the potential of proteomics-driven biomarker discovery to address clinical unmet needs.